| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 165 |
| 1 | RITUXIMAB | 142 |
| 2 | IBRITUMOMAB TIUXETAN | 128 |
| 3 | CARBOPLATIN | 125 |
| 4 | ETOPOSIDE | 125 |
| 5 | DOXORUBICIN | 121 |
| 6 | IFOSFAMIDE | 119 |
| 7 | FILGRASTIM | 116 |
| 8 | CISPLATIN | 115 |
| 9 | FLUDARABINE PHOSPHATE | 113 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBRITUMOMAB TIUXETAN | 128 | 0.0840 |
| 1 | STREPTOMYCIN | 11 | 0.0096 |
| 2 | PYRAZINAMIDE | 90 | 0.0095 |
| 3 | GRANULOCYTE COLONY STIMULATING FACTOR | 20 | 0.0092 |
| 4 | ISONIAZID | 92 | 0.0056 |
| 5 | RIFAMPICIN | 49 | 0.0049 |
| 6 | TINIDAZOLE | 2 | 0.0045 |
| 7 | ETHAMBUTOL HYDROCHLORIDE | 10 | 0.0037 |
| 8 | BEDAQUILINE FUMARATE | 5 | 0.0035 |
| 9 | FILGRASTIM | 116 | 0.0031 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 259 |
| 1 | Alkylating Drug [EPC] | 149 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 143 |
| 3 | Platinum-based Drug [EPC] | 127 |
| 4 | Topoisomerase Inhibitor [EPC] | 125 |
| 5 | Leukocyte Growth Factor [EPC] | 117 |
| 6 | Antimycobacterial [EPC] | 111 |
| 7 | Tumor Necrosis Factor Blocker [EPC] | 102 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 78 |
| 9 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 61 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antimycobacterial [EPC] | 111 | 0.0046 |
| 1 | Vasopressin Receptor Agonist [EPC] | 1 | 0.0030 |
| 2 | Topoisomerase Inhibitor [EPC] | 125 | 0.0016 |
| 3 | CD52-directed Cytolytic Antibody [EPC] | 29 | 0.0015 |
| 4 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 34 | 0.0014 |
| 5 | Osmotic Diuretic [EPC] | 7 | 0.0013 |
| 6 | Oxazolidinone Antibacterial [EPC] | 33 | 0.0011 |
| 7 | Anthelmintic [EPC] | 3 | 0.0010 |
| 8 | Rifamycin Antibacterial [EPC] | 31 | 0.0009 |
| 9 | Leukocyte Growth Factor [EPC] | 117 | 0.0008 |